New Simple, 15-Minute Sample-to-Answer COVID-19 Test Used with Desktop Detection System Costs Less than USD 2
By HospiMedica International staff writers Posted on 03 Feb 2021 |
Image: The HMNTL team displays new COVID-19 antibody test. At the top left corner is a PRAM image in which each black dot represents one detected COVID-19 antibody molecule (Photo courtesy of University of Illinois)
A simple, 15-minute sample-to-answer antibody test that costs less than USD 2 and is used with a desktop detection system could make COVID-19 testing more fast, cheap, and accessible.
The cost efficient COVID-19 antibody test developed by researchers from the Holonyak Micro & Nanotechnology Lab at The Grainger College of Engineering University of Illinois (Urbana, IL, USA) is based on a “flu chip” that was being developed before the pandemic to rapidly determine the most likely cause of a fever by measuring several proteins within a droplet of blood.
Serological (detected by blood sample) antibody testing is an important diagnostic tool for combating the COVID-19 pandemic. Studies have shown that measurement of SARS-CoV-2 specific antibodies may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections – a cause for concern as vaccinations may lessen or eliminate symptoms as well as prevent infection. Quantitative measurement of COVID-19 antibody titer is also vital for blood transfusion therapy, which has shown promising results for treating patients with severe symptoms.
The new highly sensitive, fast, and low-cost test demonstrates great potential for wide applications in diverse working environments. COVID antibody testing could become routine and simple as a variety of vaccines are deployed whose long-term protection is not yet fully known. The test is simple enough to be performed at schools, health clinics, pharmacies, and parts of the world where diagnostic laboratories are not available.
“Compared with other detection methods, our method is a simple, 15-minute sample-to-answer test,” said Bin Zhao, a postdoctoral research associate and IGB Fellow. “It costs less than USD 2 per test and is used with a desktop detection system that is suitable for point-of-care situations like clinics and physician offices.”
“Our developed method is not only rapid and simple, but also highly sensitive and quantitative. It also requires only a fingerstick quantity of blood (~ 4 µL),” added Nantao Li, an ECE and Holonyak Lab graduate student. “The method that we used to detect COVID-19 antibody can also be adapted to detect other molecules, such as antibodies to other viral pathogens, biomarkers for cardiac disease, and biomarkers for cancer.”
Related Links:
University of Illinois
The cost efficient COVID-19 antibody test developed by researchers from the Holonyak Micro & Nanotechnology Lab at The Grainger College of Engineering University of Illinois (Urbana, IL, USA) is based on a “flu chip” that was being developed before the pandemic to rapidly determine the most likely cause of a fever by measuring several proteins within a droplet of blood.
Serological (detected by blood sample) antibody testing is an important diagnostic tool for combating the COVID-19 pandemic. Studies have shown that measurement of SARS-CoV-2 specific antibodies may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections – a cause for concern as vaccinations may lessen or eliminate symptoms as well as prevent infection. Quantitative measurement of COVID-19 antibody titer is also vital for blood transfusion therapy, which has shown promising results for treating patients with severe symptoms.
The new highly sensitive, fast, and low-cost test demonstrates great potential for wide applications in diverse working environments. COVID antibody testing could become routine and simple as a variety of vaccines are deployed whose long-term protection is not yet fully known. The test is simple enough to be performed at schools, health clinics, pharmacies, and parts of the world where diagnostic laboratories are not available.
“Compared with other detection methods, our method is a simple, 15-minute sample-to-answer test,” said Bin Zhao, a postdoctoral research associate and IGB Fellow. “It costs less than USD 2 per test and is used with a desktop detection system that is suitable for point-of-care situations like clinics and physician offices.”
“Our developed method is not only rapid and simple, but also highly sensitive and quantitative. It also requires only a fingerstick quantity of blood (~ 4 µL),” added Nantao Li, an ECE and Holonyak Lab graduate student. “The method that we used to detect COVID-19 antibody can also be adapted to detect other molecules, such as antibodies to other viral pathogens, biomarkers for cardiac disease, and biomarkers for cancer.”
Related Links:
University of Illinois
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans